Image Description

INVESTORS
& MEDIA

circle

INVESTOR OVERVIEW

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

03/15/17
( FY )
ALS

ALS

03/15/17
( FY )
SMA

SMA

03/15/17
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Negative Results From VITALITY-ALS
Phase 3 Clinical Trial of Tirasemtiv in Patients with ALS Did Not Meet Primary or Secondary Endpoints Results to be Presented December 8 th at 28th International Symposium on ALS/MND Conference Call Today at 8:30 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov.
Toggle Summary Cytokinetics Announces Additional Results From COSMIC-HF at the American Heart Association Scientific Sessions 2017
SOUTH SAN FRANCISCO, Calif. , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic  O ral  S tudy of  M yosin Activation to  I ncrease  C ontractility in  H eart  F ailure), a Phase 2 clinical trial evaluating 
Toggle Summary Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the American Heart Association Scientific Sessions 2017
SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic  O ral  S tudy of  M yosin Activation to  I ncrease  C ontractility in  H eart  F ailure), a Phase 2 trial evaluating 
Toggle Summary Cytokinetics, Inc. Reports Third Quarter 2017 Financial Results
VITALITY-ALS Proceeding towards Planned Database Lock and Read-out in Q4; Commercial Planning and Preparations for Potential Regulatory Submissions Underway CK-2127107 Advancing in Four Mid-Stage Clinical Trials Under Collaboration with Astellas First Patient Recently Dosed in Japan in GALACTIC-HF

EVENTS

There are currently no events to display.